RADNOR, PA — Advanced Aesthetic Technologies, Inc. (AAT) has announced that its partner in China, Lanzhou Biotechnique Development Co., Ltd. (LanDev), has secured regulatory approval to market Algeness® VL, a 2.5% agarose gel dermal filler. The product has been approved as a Class III medical device by the National Medical Products Administration, marking it as the first agarose-based injection filler officially authorized for use in China.
Algeness® VL is the result of years of scientific and clinical research aimed at creating a 100% natural and biodegradable injectable filler. Designed to address wrinkles and restore facial volume, this innovative product offers a distinct injection technique and a biocompatible composition that has gained recognition among global aesthetic practitioners.
LanDev, a subsidiary of China National Biotec Group (CNBG) under Sinopharm Group, played a key role in obtaining the registration license for Algeness®, reflecting its expertise in the aesthetic sector. LanDev is notably the sole domestic Chinese manufacturer of botulinum toxin, with its product Hengli holding a significant market share.
Doug Abel, President and CEO of AAT, expressed optimism about this milestone, stating, “We are excited and look forward to the entry of Algeness® into the large aesthetic market in China through our partner LanDev. We believe that LanDev is the ideal partner to maximize the success of Algeness® in China as they are the sole domestic Chinese manufacturer of botulinum toxin… This approval marks a significant accomplishment by the LanDev, CNBG, AAT, and Ghimas teams and our regulatory advisors and partners.”
This approval caps off a series of significant achievements for AAT over the last two years, including advancing its US FDA Pre-Market Authorization clinical trial, obtaining the CE Mark under Medical Device Regulations (MDR), and acquiring a controlling interest in Ghimas, S.p.A., the original developer of Algeness®.
Practitioners globally have praised Algeness® for its unique formulation and clinical results. Dr. Omer Buhsem, a plastic surgeon and Medical Director for Algeness®, emphasized its benefits, noting, “With my patients, I am uniquely able to define the desired shape while working with a product that I have found to be very safe.”
Additionally, dermatologist Dr. Tatjana Pavicic of Munich, Germany, called Algeness® a “true revolution in the field of aesthetic medicine,” highlighting its natural composition, biocompatibility, and patient satisfaction with results.
The approval of Algeness® VL in China signals a pivotal step for Advanced Aesthetic Technologies, further expanding its reach in the growing global market for aesthetic solutions.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.